Research Analysts Set Expectations for DNTH Q1 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Stock analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued on Wednesday, March 12th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.74) per share for the quarter, down from their previous forecast of ($0.62). Wedbush has a “Outperform” rating and a $36.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.11) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($2.75) EPS and FY2029 earnings at $1.79 EPS.

DNTH has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday. TD Cowen started coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Guggenheim restated a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

Shares of Dianthus Therapeutics stock opened at $21.33 on Friday. The business has a 50-day moving average price of $22.61 and a two-hundred day moving average price of $24.92. Dianthus Therapeutics has a 1-year low of $18.13 and a 1-year high of $33.77. The company has a market cap of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in Dianthus Therapeutics in the 3rd quarter valued at about $556,000. Barclays PLC lifted its position in Dianthus Therapeutics by 390.5% in the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after acquiring an additional 33,185 shares in the last quarter. HighVista Strategies LLC bought a new position in Dianthus Therapeutics in the 3rd quarter valued at about $542,000. State Street Corp lifted its position in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after acquiring an additional 97,362 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.